ClinicalTrials.gg
Not yet recruitingNCT06451276Updated Jun 11, 2024

The Effectiveness of Adhesive Versus Conventional Nasoalveolar Molding on Children With Unilateral Cleft Lip and Palate

An interventional study of Nasoalveolar molding in unilateral cleft lip and palate in Cleft Lip and Palate, sponsored by Al-Azhar University. Not yet recruiting at 2 sites in Egypt. Open to participants aged 7 Days to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
7 Days to 12 Weeks
Sex
All
01

Study summary

The present study will compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate.

objectives: -

  1. Evaluation of the anatomical position of the greater and lesser segments of the maxilla related to a stable midline anatomical point.
  2. Evaluation of the nasal symmetry.
Read the detailed description

cleft lip and palate can manifest as an independent anomaly, be associated with a syndrome, or present as a complex condition. Unilateral clefts are notably more common, occurring nine times more frequently than bilateral clefts. Additionally, it predominantly affects males, with a male-to-female ratio of 2:1. Common clinical features in unilateral cleft lip and palate cases involve structural changes in the nose, lip, palate, and alveolar arch. Peri-oral tissues lack continuity, and on the affected side of the nose, you can observe wider nostrils and a downward-pointing alar rim. Additionally, the columella and nasal tip shift towards the unaffected or normal side, accompanied by the displacement of the maxillary alveolar segments towards the lateral side.

Conventional treatment for cleft lip and palate historically comprised numerous surgical procedures, including secondary revisions and alveolar bone grafting. However, even with these multiple interventions, concerns persisted regarding suboptimal aesthetics. Therefore, the pursuit of non-surgical treatment options that can mitigate the severity of this deformity during early life is greatly desirable. The introduction of the presurgical Nasoalveolar molding (NAM) procedure has offered an alternative, allowing for the avoidance of traditional secondary surgeries while achieving improved outcomes. . These interventions should be initiated within the narrow time frame from birth to four months, as estrogen levels decrease within the first four months after birth, making this period optimal for tissue manipulation.

02

Conditions studied

  • Cleft Lip and Palate

Browse trials for

03

In context

Cleft Lip

168 studies on the registry are indexed under Cleft Lip; 51 are open to participants now.

This study's planned enrollment of 30 is close to the median of 30 across 116 interventional studies indexed under Cleft Lip.

Browse Cleft Lip studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Days to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 1- 8 weeks.
  • Gender: male and female.
  • Patients with a unilateral cleft alveolus and lip.
  • No developmental syndromes or atypical cleft pathology in medical history.
  • No previous history of unilateral CLP correction.
  • Motivated parents toward the treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients with a bilateral cleft alveolus and lip
  • Syndromic patient
  • Uncooperative caregiver
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Adhesive nasoalveolar molding (GS-NAM)

    3D (3 dimensional ) printed conventional NAM in thickness of 2 mm. The cleft area will be blocked in software, and NAM will be fabricated using a 3D (3 dimensional ) printer. Soft acrylic resin will be added to make pressure area and reduction in opposing for relief. The appliance will be evaluated and adjusted monthly. A nasal stent will be fabricated when the cleft is 5mm

    Device: Nasoalveolar molding in unilateral cleft lip and palate

  • Experimental
    Conventional nasoalveolar molding

    (positive control group) comprises 10 cases of unilateral cleft lip and palate that will be scheduled for construction of 3D (3 dimensional ) printed conventional NAM in thickness of 2 mm. The cleft area will be blocked in software, and NAM will be fabricated using a 3D printer. Soft acrylic resin will be added to make pressure area and reduction in opposing for relief. The appliance will be evaluated and adjusted monthly. A nasal stent will be fabricated when the cleft is 5mm

    Device: Nasoalveolar molding in unilateral cleft lip and palate

  • No intervention
    normal children

    normal children which will be compared with groups 1 and 2 for results evaluation

Interventions

  • DeviceNasoalveolar molding in unilateral cleft lip and palate

    compare the effectiveness of adhesive nasoalveolar molding (GS-NAM) and conventional nasoalveolar molding on the alveolar ridge, nasal, and labial growth in children with unilateral cleft lip and palate

    Also known as: NAM

06

What researchers measure

Primary outcomes

  1. Posterior ends of alveolar crest

    width between the most posterior ends of the alveolar crest in the greater segment and lesser segment

    Time frame: 3 months

  2. Middle ends of alveolar crest

    width between the middle parts of the cleft palate (The intersection points between the palatally extended buccal frenum sulcus line and the palatal gingival groove in the greater and lesser segment

    Time frame: 3 months

  3. Anterior ends of alveolar crest

    The widths of the cleft gap (The anterior endpoint of the alveolar crest in the greater and lesser segment)

    Time frame: 3 months

  4. Mid line of maxilla

    Inc-Sagittal: - Perpendicular distance from Inc point (The intersection points between the labial frenum-incisive papilla point line and the alveolar crest of the premaxilla in the greater segment) to sagittal line (The perpendicular line to the PG-PL line)

    Time frame: 3 months

  5. Angulation of maxilla

    Mid-Inc)-Sagittal: - Angle among Inc point, midpoint in PG -PL, and sagittal line

    Time frame: 3 months

Secondary outcomes

  1. Alar base width

    Total width correction of alar base width.

    Time frame: 3 months

  2. Columella length.

    Columella length correction

    Time frame: 3 months

  3. Columella angle deviation.

    Columella angle deviation correction

    Time frame: 3 months

  4. Nostril height and width on the cleft side.

    Nostril height and width on the cleft side correction

    Time frame: 3 months

  5. Nostril height and width on the non-cleft side

    Nostril height and width on the non-cleft side correction

    Time frame: 3 months

  6. Nasal ridge deviation.

    Nasal ridge deviation correction

    Time frame: 3 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: 4 months

Access criteria: all IPD that underlie results in a publication

Data sharing details ↗ · gmail.com

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06451276
Responsible party
Ahmed Farghly Abdelnaeem Ahmed (Doctor, Al-Azhar University) — Principal investigator
First posted
Jun 11, 2024
Start date
Jul 20, 2024 (estimated)
Primary completion
Jul 20, 2025 (estimated)
Completion
Aug 20, 2025 (estimated)
Last update
Jun 11, 2024

Study contacts

Ahmed F Ahmed, Master
Contact
Ahmedfarghly0@gmail.com
00201009050985
Adel F Hassan, Phd
Contact
Adelfathy@azhar.edu.eg
00201124591323
Adel F Hassan, Phd
study director · Fucalty of dental medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion